US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexeo Therapeutics

2.64

-0.3050-10.36%

Post-market: 2.56-0.0800-3.03%16:31 EDT

Volume:624.83K

Turnover:1.67M

Market Cap:87.64M

PE:-0.85

High:2.93

Open:2.81

Low:2.55

Close:2.95

Loading ...

Overview Company News Filings

Lexeo Therapeutics appoints Rasbach as Chief Financial Officer

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

THOMSON REUTERS

Press Release: Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

Lexeo Therapeutics Files $300 Million Mixed Shelf Registration

MT Newswires Live

Paula H. Cholmondeley Bought 96% More Shares In Lexeo Therapeutics

Simply Wall St.

Lexeo Therapeutics’ Promising Gene Therapy Progress and Strong Financial Position Present Attractive Investment Opportunity

Lexeo Therapeutics Advances Cardiac Portfolio Amid Financial Report

Lexeo Therapeutics, Inc. (LXEO) Gets a Buy from RBC Capital

Lexeo Therapeutics price target raised to $23 from $21 at H.C. Wainwright

Lexeo Therapeutics Is Maintained at Outperform by Leerink Partners

Lexeo Therapeutics price target raised to $25 from $23 at Chardan

Lexeo Therapeutics price target lowered to $19 from $20 at Leerink

BUZZ-Lexeo rises on alignment with FDA on development plan for gene therapy

Lexeo Therapeutics reaches FDA alignment on development plan for LX2006

Lexeo Therapeutics Inc: Believes Cash and Cash Equivalents as of Sept 30 Will Be Sufficient to Fund Operations Into 2027

THOMSON REUTERS

Press Release: Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Adage Capital Management, L.p. Reports 7.86% Passive Stake in Lexeo Therapeutics as of Sept 30 - SEC Filing

THOMSON REUTERS

Lexeo Therapeutics Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Lexeo Therapeutics Sees 'Positive' Interim Results for LX1001 to Treat APOE4-Linked Alzheimer's Disease

MT Newswires Live

Cautious Optimism for Lexeo Therapeutics’ LX1001: Encouraging Interim Results and Investment Potential

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LXEO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LXEO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LXEO\",,,,,undefined,":{"symbol":"LXEO","market":"US","secType":"STK","nameCN":"Lexeo Therapeutics","latestPrice":2.64,"timestamp":1743710400000,"preClose":2.945,"halted":0,"volume":624826,"hourTrading":{"tag":"盘后","latestPrice":2.56,"preClose":2.64,"latestTime":"16:31 EDT","volume":2472,"amount":6465.92,"timestamp":1743712315331},"delay":0,"floatShares":21814872,"shares":33196997,"eps":-3.093449,"marketStatus":"Closed","change":-0.305,"latestTime":"04-03 16:00:00 EDT","open":2.81,"high":2.925,"low":2.5501,"amount":1667831.4214283999,"amplitude":0.127301,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.093449,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743753600000},"marketStatusCode":5,"adr":0,"listingDate":1698984000000,"exchange":"NASDAQ","adjPreClose":2.945,"preHourTrading":{"tag":"盘前","latestPrice":2.92,"preClose":2.945,"latestTime":"09:24 EDT","volume":31,"amount":89.4200022,"timestamp":1743686656922},"postHourTrading":{"tag":"盘后","latestPrice":2.56,"preClose":2.64,"latestTime":"16:31 EDT","volume":2472,"amount":6465.92,"timestamp":1743712315331},"volumeRatio":1.441571,"impliedVol":1.3232,"impliedVolPercentile":0.4487},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LXEO\",,,,,undefined,":{"symbol":"LXEO","floatShares":21814872,"roa":"-46.11%","roe":"-85.37%","lyrEps":-3.093449,"volumeRatio":1.441571,"shares":33196997,"dividePrice":0,"high":2.925,"amplitude":0.127301,"preClose":2.945,"low":2.5501,"week52Low":2.32,"pbRate":"0.75","week52High":19.5,"institutionHeld":0,"latestPrice":2.64,"eps":-3.093449,"divideRate":0,"volume":624826,"delay":0,"ttmEps":-3.093449,"open":2.81,"prevYearClose":6.58,"prevWeekClose":4.1,"prevMonthClose":3.47,"prevQuarterClose":3.47,"fiveDayClose":4.11,"twentyDayClose":2.81,"sixtyDayClose":7.13},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LXEO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2492920121","title":"Lexeo Therapeutics appoints Rasbach as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492920121","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492920121?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:06","pubTimestamp":1734609969,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics (LXEO) announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, CFO, effective immediately. Most recently, Dr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-appoints-rasbach-as-chief-financial-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-appoints-rasbach-as-chief-financial-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2492198129","title":"Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492198129","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492198129?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:00","pubTimestamp":1734609602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUA3GWDWB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2492291321","title":"Press Release: Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492291321","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492291321?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:00","pubTimestamp":1734609600,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec. 19, 2024  -- Lexeo Therapeutics, Inc. , a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therapy programs.\"Kyle has an exceptional track record as an operator and life sciences portfolio manager, and we are excited to welcome him to Lexeo at a time when we are advancing our pipeline and transitioning towards pivotal studies,\" said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. \"His experience in strategic planning, financial management and business development, combined with his scientific background, will complement our management team and support Lexeo's continued growth into 2025.\". Lexeo Therape","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2491716213","title":"Lexeo Therapeutics Files $300 Million Mixed Shelf Registration","url":"https://stock-news.laohu8.com/highlight/detail?id=2491716213","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491716213?lang=en_us&edition=fundamental","pubTime":"2024-12-13 23:29","pubTimestamp":1734103783,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics  filed a registration statement Friday with the US Securities and Exchange Commission for the potential sale of up to $300 million of its securities via one or more offerings.The registration covers common stock, preferred stock, debt securities, warrants, subscription rights, purchase contracts, and units, according to the filing.The company said it will outline how it plans to use the proceeds from the sale of securities in a prospectus supplement.Price: 7.12, Change: -0.01, Percent Change: -0.14","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2486139150","title":"Paula H. Cholmondeley Bought 96% More Shares In Lexeo Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2486139150","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486139150?lang=en_us&edition=fundamental","pubTime":"2024-11-28 18:18","pubTimestamp":1732789083,"startTime":"0","endTime":"0","summary":"Potential Lexeo Therapeutics, Inc.  shareholders may wish to note that the Independent Director, Paula H. Cholmondeley, recently bought US$105k worth of stock, paying US$6.99 for each share. We reckon that's a good sign, especially since the purchase boosted their holding by 96%.The Last 12 Months Of Insider Transactions At Lexeo Therapeutics. In fact, the recent purchase by Paula H. Cholmondeley was the biggest purchase of Lexeo Therapeutics shares made by an insider individual in the last twelve months, according to our records. Even though the purchase was made at a significantly lower price than the recent price , we still think insider buying is a positive. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.You can see a visual depiction of insider transactions  over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share pr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/paula-h-cholmondeley-bought-96-101803558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2485897434","title":"Lexeo Therapeutics’ Promising Gene Therapy Progress and Strong Financial Position Present Attractive Investment Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2485897434","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485897434?lang=en_us&edition=fundamental","pubTime":"2024-11-21 14:36","pubTimestamp":1732170979,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics, Inc. (LXEO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Brian S...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lexeo-therapeutics-promising-gene-therapy-progress-and-strong-financial-position-present-attractive-investment-opportunity?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lexeo-therapeutics-promising-gene-therapy-progress-and-strong-financial-position-present-attractive-investment-opportunity?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4097","LXEO","PRGS","LU2065732104.USD"],"gpt_icon":0},{"id":"2483394246","title":"Lexeo Therapeutics Advances Cardiac Portfolio Amid Financial Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2483394246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483394246?lang=en_us&edition=fundamental","pubTime":"2024-11-15 12:35","pubTimestamp":1731645327,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics, Inc. ( ($LXEO) ) has released its Q3 earnings. Here is a breakdown of the information Lexeo Therapeutics, Inc. presented to its...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lexeo-therapeutics-advances-cardiac-portfolio-amid-financial-report?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lexeo-therapeutics-advances-cardiac-portfolio-amid-financial-report?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2483626463","title":"Lexeo Therapeutics, Inc. (LXEO) Gets a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2483626463","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483626463?lang=en_us&edition=fundamental","pubTime":"2024-11-15 09:48","pubTimestamp":1731635331,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Luca Issi maintained a Buy rating on Lexeo Therapeutics, Inc. (LXEO – Research Report) on November 13 and set a price target of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lexeo-therapeutics-inc-lxeo-gets-a-buy-from-rbc-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lexeo-therapeutics-inc-lxeo-gets-a-buy-from-rbc-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","BK4139","LXEO"],"gpt_icon":0},{"id":"2483587830","title":"Lexeo Therapeutics price target raised to $23 from $21 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2483587830","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483587830?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:16","pubTimestamp":1731582967,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Lexeo Therapeutics (LXEO) to $23 from $21 and keeps a Buy rating on the shares after alignment wa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-raised-to-23-from-21-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-raised-to-23-from-21-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO"],"gpt_icon":0},{"id":"2483858809","title":"Lexeo Therapeutics Is Maintained at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2483858809","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483858809?lang=en_us&edition=fundamental","pubTime":"2024-11-14 02:10","pubTimestamp":1731521400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2024 13:10 ET (18:10 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2483858469","title":"Lexeo Therapeutics price target raised to $25 from $23 at Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2483858469","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483858469?lang=en_us&edition=fundamental","pubTime":"2024-11-14 02:05","pubTimestamp":1731521158,"startTime":"0","endTime":"0","summary":"Chardan analyst Geulah Livshits raised the firm’s price target on Lexeo Therapeutics (LXEO) to $25 from $23 and keeps a Buy rating on the shares. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-raised-to-25-from-23-at-chardan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-raised-to-25-from-23-at-chardan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO"],"gpt_icon":0},{"id":"2483833141","title":"Lexeo Therapeutics price target lowered to $19 from $20 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2483833141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483833141?lang=en_us&edition=fundamental","pubTime":"2024-11-13 23:55","pubTimestamp":1731513317,"startTime":"0","endTime":"0","summary":"Leerink lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $19 from $20 and keeps an Outperform rating on the shares. The firm notes L...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-lowered-to-19-from-20-at-leerink?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-lowered-to-19-from-20-at-leerink?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO"],"gpt_icon":0},{"id":"2483588999","title":"BUZZ-Lexeo rises on alignment with FDA on development plan for gene therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2483588999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483588999?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:28","pubTimestamp":1731508104,"startTime":"0","endTime":"0","summary":"** Shares of gene therapy developer Lexeo Therapeutics  rise 13.62% to $8.74 premarket   ** Co says reached alignment with FDA on registrational development plan for LX2006 to support an accelerated approval pathway   ** LX2006 is being developed as a gene therapy that is delivered intravenously for the treatment of Friedreich's ataxia cardiomyopathy   ** Friedreich's ataxia is a genetic multi-system disorder and 80% of patients are estimated to develop cardiomyopathy, a type of heart disease   ** LX2006 was granted regenerative medicine advanced therapy  designation to accelerate development - LXEO   ** Brokerage Stifel says alignment is a big win   ** Up to last close, stock down ~42% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2483974002","title":"Lexeo Therapeutics reaches FDA alignment on development plan for LX2006","url":"https://stock-news.laohu8.com/highlight/detail?id=2483974002","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483974002?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:56","pubTimestamp":1731502576,"startTime":"0","endTime":"0","summary":"LX2006 for the Treatment of FA Cardiomyopathy: Regulatory Update: Alignment on key elements of accelerated development pathway following a Type C m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-reaches-fda-alignment-on-development-plan-for-lx2006?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-reaches-fda-alignment-on-development-plan-for-lx2006?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4535","BK4130","FA","BK4539","LXEO"],"gpt_icon":0},{"id":"2483001507","title":"Lexeo Therapeutics Inc: Believes Cash and Cash Equivalents as of Sept 30 Will Be Sufficient to Fund Operations Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2483001507","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483001507?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:30","pubTimestamp":1731501001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA1XDQTC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2483013670","title":"Press Release: Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483013670","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483013670?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:30","pubTimestamp":1731501000,"startTime":"0","endTime":"0","summary":"Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index  and frataxin protein expression as co-primary registrational endpoints. Received RMAT designation for LX2006 for the treatment of Friedreich ataxia  cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA. Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials. Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial; initial clinical data including safety and biodistribution on track for late Q1 / early Q2 2025","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO","BK4539","BK4139","FA","IHC","BK4130","BK4535","ARIA","BK4162"],"gpt_icon":0},{"id":"2482818250","title":"Adage Capital Management, L.p. Reports 7.86% Passive Stake in Lexeo Therapeutics as of Sept 30 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2482818250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482818250?lang=en_us&edition=fundamental","pubTime":"2024-11-12 23:10","pubTimestamp":1731424236,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nFWN3MJ17R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2479877088","title":"Lexeo Therapeutics Price Target Maintained With a $21.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2479877088","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479877088?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:52","pubTimestamp":1730375520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2024 07:52 ET (11:52 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2479733963","title":"Lexeo Therapeutics Sees 'Positive' Interim Results for LX1001 to Treat APOE4-Linked Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2479733963","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479733963?lang=en_us&edition=fundamental","pubTime":"2024-10-30 23:04","pubTimestamp":1730300655,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics  said Wednesday it has seen \"positive\" interim data from a phase 1/2 trial of LX1001 to treat APOE4-associated Alzheimer's disease.Treatment with the gene therapy candidate resulted in \"dose-dependent increases in APOE2 protein expression and improvements in AD-associated tau biomarkers, measures which have been closely correlated with cognitive outcomes,\" the company said.The candidate drug also showed a \"favorable safety profile,\" the company said.Lexeo said it has started engagement with the US Food and Drug Administration on the results and plans to provide an update on interactions with the regulator and more LX1001 development plans next year.The company's shares fell nearly 10% in recent trading.Price: 8.98, Change: -0.99, Percent Change: -9.93","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2479781470","title":"Cautious Optimism for Lexeo Therapeutics’ LX1001: Encouraging Interim Results and Investment Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2479781470","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479781470?lang=en_us&edition=fundamental","pubTime":"2024-10-30 22:15","pubTimestamp":1730297711,"startTime":"0","endTime":"0","summary":"Analyst Geulah Livshits of Chardan Capital reiterated a Buy rating on Lexeo Therapeutics, Inc. (LXEO – Research Report), retaining the price target...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cautious-optimism-for-lexeo-therapeutics-lx1001-encouraging-interim-results-and-investment-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cautious-optimism-for-lexeo-therapeutics-lx1001-encouraging-interim-results-and-investment-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXEO"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":49}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LXEO\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LXEO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LXEO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1718251200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LXEO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LXEO","date":"2025-04-02","current":-1.056681,"percent":0.975904,"low":-8.903248,"twenty":-6.340916,"median":-4.836113,"eighty":-2.503353,"high":-0.893823,"avg":-4.584736,"sd":1.984176,"marketCap":103906600},"quantilePoints":[{"date":"2023-11-03","current":-4.257819,"twenty":-4.257819,"median":-4.257819,"eighty":-4.257819,"marketCap":271355051},{"date":"2023-11-10","current":-4.199758,"twenty":-4.199758,"median":-4.091377,"eighty":-4.048799,"marketCap":267654754},{"date":"2023-11-17","current":-4.292656,"twenty":-4.257819,"median":-4.118472,"eighty":-4.064282,"marketCap":273575228},{"date":"2023-11-24","current":-4.373941,"twenty":-4.270979,"median":-4.199758,"eighty":-4.070475,"marketCap":278755643},{"date":"2023-12-01","current":-4.923587,"twenty":-4.377038,"median":-4.259754,"eighty":-4.081313,"marketCap":313785113},{"date":"2023-12-08","current":-5.031968,"twenty":-4.945263,"median":-4.26556,"eighty":-4.111505,"marketCap":320692333},{"date":"2023-12-15","current":-4.58828,"twenty":-4.855461,"median":-4.333298,"eighty":-4.161824,"marketCap":306423687},{"date":"2023-12-22","current":-5.849059,"twenty":-5.408075,"median":-4.389424,"eighty":-4.194339,"marketCap":390623587},{"date":"2023-12-29","current":-5.805172,"twenty":-5.505138,"median":-4.537237,"eighty":-4.207282,"marketCap":387692577},{"date":"2024-01-05","current":-5.857039,"twenty":-5.805172,"median":-4.621669,"eighty":-4.218567,"marketCap":391156497},{"date":"2024-01-12","current":-5.896937,"twenty":-5.857039,"median":-4.799136,"eighty":-4.257819,"marketCap":393821051},{"date":"2024-01-19","current":-6.012642,"twenty":-5.955803,"median":-4.957419,"eighty":-4.257819,"marketCap":401548257},{"date":"2024-01-26","current":-6.66298,"twenty":-6.148663,"median":-5.403559,"eighty":-4.260916,"marketCap":444980484},{"date":"2024-02-02","current":-6.706868,"twenty":-6.322251,"median":-5.468033,"eighty":-4.26169,"marketCap":447911493},{"date":"2024-02-09","current":-6.714848,"twenty":-6.590366,"median":-5.777243,"eighty":-4.264786,"marketCap":448444404},{"date":"2024-02-16","current":-6.072489,"twenty":-6.589568,"median":-5.827115,"eighty":-4.287237,"marketCap":405545088},{"date":"2024-02-23","current":-6.343796,"twenty":-6.544084,"median":-5.876988,"eighty":-4.341427,"marketCap":423664054},{"date":"2024-03-01","current":-5.8331,"twenty":-6.543286,"median":-5.916886,"eighty":-4.373941,"marketCap":389557765},{"date":"2024-03-08","current":-5.857039,"twenty":-6.520145,"median":-5.890953,"eighty":-4.383231,"marketCap":391156497},{"date":"2024-03-15","current":-6.292966,"twenty":-6.520145,"median":-5.916886,"eighty":-4.447485,"marketCap":417815207},{"date":"2024-03-22","current":-6.028084,"twenty":-6.505782,"median":-5.977118,"eighty":-4.547445,"marketCap":400228597},{"date":"2024-03-28","current":-6.128418,"twenty":-6.497802,"median":-5.937219,"eighty":-4.601636,"marketCap":406890192},{"date":"2024-04-05","current":-5.265543,"twenty":-6.474661,"median":-5.932845,"eighty":-4.625869,"marketCap":349600479},{"date":"2024-04-12","current":-5.241463,"twenty":-6.410602,"median":-5.90231,"eighty":-4.683238,"marketCap":348001696},{"date":"2024-04-19","current":-4.844139,"twenty":-6.359022,"median":-5.876988,"eighty":-4.791277,"marketCap":321621782},{"date":"2024-04-26","current":-4.88026,"twenty":-6.350977,"median":-5.858281,"eighty":-4.83704,"marketCap":324019956},{"date":"2024-05-03","current":-6.182772,"twenty":-6.32828,"median":-5.876988,"eighty":-4.840714,"marketCap":410498948},{"date":"2024-05-10","current":-6.881509,"twenty":-6.410602,"median":-5.90231,"eighty":-4.84735,"marketCap":477707444},{"date":"2024-05-17","current":-6.653707,"twenty":-6.497802,"median":-5.932845,"eighty":-4.860193,"marketCap":461893680},{"date":"2024-05-24","current":-7.346604,"twenty":-6.546981,"median":-6.018356,"eighty":-4.875444,"marketCap":509993878},{"date":"2024-05-31","current":-7.617118,"twenty":-6.584345,"median":-6.028342,"eighty":-4.885879,"marketCap":528772723},{"date":"2024-06-07","current":-8.28154,"twenty":-6.629029,"median":-6.03658,"eighty":-4.908353,"marketCap":574896200},{"date":"2024-06-14","current":-8.903248,"twenty":-6.66298,"median":-6.072489,"eighty":-4.908353,"marketCap":618054597},{"date":"2024-06-21","current":-7.441521,"twenty":-6.711656,"median":-6.103378,"eighty":-4.917985,"marketCap":516582946},{"date":"2024-06-28","current":-7.05236,"twenty":-6.714848,"median":-6.103378,"eighty":-4.921032,"marketCap":489567767},{"date":"2024-07-05","current":-7.066597,"twenty":-6.782675,"median":-6.120366,"eighty":-4.923587,"marketCap":490556127},{"date":"2024-07-12","current":-8.276794,"twenty":-6.842522,"median":-6.15029,"eighty":-4.991251,"marketCap":574566747},{"date":"2024-07-15","current":-8.352728,"twenty":-6.873712,"median":-6.156275,"eighty":-4.995541,"marketCap":579838001},{"date":"2024-08-02","current":-6.198104,"twenty":-6.865914,"median":-6.161186,"eighty":-4.999831,"marketCap":430266153},{"date":"2024-08-09","current":-5.54792,"twenty":-6.840926,"median":-6.144305,"eighty":-5.014306,"marketCap":385131036},{"date":"2024-08-16","current":-5.180835,"twenty":-6.826318,"median":-6.112265,"eighty":-5.010821,"marketCap":400038148},{"date":"2024-08-23","current":-5.215088,"twenty":-6.797868,"median":-6.103378,"eighty":-5.014306,"marketCap":402683028},{"date":"2024-08-30","current":-4.975314,"twenty":-6.782675,"median":-6.066504,"eighty":-4.996865,"marketCap":384168866},{"date":"2024-09-06","current":-4.881117,"twenty":-6.774695,"median":-6.03259,"eighty":-4.924513,"marketCap":376895445},{"date":"2024-09-13","current":-4.22602,"twenty":-6.738787,"median":-6.028084,"eighty":-4.89684,"marketCap":326312109},{"date":"2024-09-20","current":-4.461512,"twenty":-6.721232,"median":-5.996218,"eighty":-4.873838,"marketCap":344495661},{"date":"2024-09-27","current":-3.814978,"twenty":-6.714848,"median":-5.932845,"eighty":-4.83926,"marketCap":294573545},{"date":"2024-10-04","current":-3.900612,"twenty":-6.71405,"median":-5.90231,"eighty":-4.736975,"marketCap":301185746},{"date":"2024-10-11","current":-3.408218,"twenty":-6.71006,"median":-5.876988,"eighty":-4.623769,"marketCap":263165591},{"date":"2024-10-18","current":-3.89633,"twenty":-6.698313,"median":-5.858281,"eighty":-4.466448,"marketCap":300855136},{"date":"2024-10-25","current":-4.238865,"twenty":-6.663872,"median":-5.849059,"eighty":-4.397847,"marketCap":327303939},{"date":"2024-10-31","current":-3.543091,"twenty":-6.66298,"median":-5.819389,"eighty":-4.373941,"marketCap":273579808},{"date":"2024-11-08","current":-3.378247,"twenty":-6.65417,"median":-5.783228,"eighty":-4.26556,"marketCap":260851321},{"date":"2024-11-15","current":-2.970727,"twenty":-6.653707,"median":-5.678921,"eighty":-4.257819,"marketCap":257253067},{"date":"2024-11-22","current":-2.367417,"twenty":-6.629978,"median":-5.544882,"eighty":-4.208893,"marketCap":205008871},{"date":"2024-11-29","current":-3.142556,"twenty":-6.626181,"median":-5.512207,"eighty":-4.166207,"marketCap":272132743},{"date":"2024-12-06","current":-2.703438,"twenty":-6.607553,"median":-5.450079,"eighty":-4.100138,"marketCap":234106904},{"date":"2024-12-13","current":-2.72253,"twenty":-6.599941,"median":-5.414849,"eighty":-4.066934,"marketCap":235760202},{"date":"2024-12-20","current":-2.306323,"twenty":-6.589568,"median":-5.281597,"eighty":-3.914314,"marketCap":199718319},{"date":"2024-12-27","current":-2.588885,"twenty":-6.578686,"median":-5.241463,"eighty":-3.893837,"marketCap":224187120},{"date":"2025-01-03","current":-2.546883,"twenty":-6.570706,"median":-5.215088,"eighty":-3.826967,"marketCap":220549866},{"date":"2025-01-10","current":-2.604159,"twenty":-6.564766,"median":-5.210806,"eighty":-3.754178,"marketCap":225509758},{"date":"2025-01-17","current":-1.981757,"twenty":-6.550955,"median":-5.17013,"eighty":-3.659982,"marketCap":171612264},{"date":"2025-01-24","current":-2.142882,"twenty":-6.53506,"median":-5.110187,"eighty":-3.528106,"marketCap":185565027},{"date":"2025-01-31","current":-2.005371,"twenty":-6.527327,"median":-5.031968,"eighty":-3.425345,"marketCap":173657111},{"date":"2025-02-07","current":-2.070307,"twenty":-6.515357,"median":-5.011134,"eighty":-3.395373,"marketCap":179280293},{"date":"2025-02-14","current":-1.611936,"twenty":-6.499398,"median":-4.991251,"eighty":-3.192195,"marketCap":139587239},{"date":"2025-02-21","current":-1.539361,"twenty":-6.496206,"median":-4.928215,"eighty":-3.10819,"marketCap":133302506},{"date":"2025-02-28","current":-1.142107,"twenty":-6.453914,"median":-4.914373,"eighty":-2.892068,"marketCap":98901859},{"date":"2025-03-07","current":-1.073351,"twenty":-6.437026,"median":-4.893962,"eighty":-2.779043,"marketCap":92947901},{"date":"2025-03-14","current":-1.134467,"twenty":-6.376035,"median":-4.880688,"eighty":-2.703438,"marketCap":98240308},{"date":"2025-03-21","current":-1.027514,"twenty":-6.356851,"median":-4.852166,"eighty":-2.601104,"marketCap":88978596},{"date":"2025-03-28","current":-1.387527,"twenty":-6.34619,"median":-4.840506,"eighty":-2.545356,"marketCap":136439657},{"date":"2025-04-02","current":-1.056681,"twenty":-6.340916,"median":-4.836113,"eighty":-2.503353,"marketCap":103906600}],"updateTime":1743731210306}}}